DOCK2 is a microglial specific regulator of central nervous system innate immunity found in normal and Alzheimer's disease brain

American Journal of Pathology

Volumn 175, Issue 4, 2009, Pages 1622-1630

  Cimino, Patrick J ^a   Sokal, Izabela ^a   Leverenz, James ^a   Fukui, Yoshinori ^b,c   Montine, Thomas J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b KYUSHU UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DEDICATOR OF CYTOKINESIS 2; PROSTAGLANDIN; PROSTAGLANDIN E RECEPTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; MALE; MICROGLIA; MOUSE; NONHUMAN; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 73549084087     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.090443     Document Type: Article

References (63)

1. Lobsiger CS, Cleveland DW: Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci 2007, 10:1355-1360
2. Cimino PJ, Keene CD, Breyer RM, Montine KS, Montine TJ: Therapeutic targets in prostaglandin E2 signaling for neurologic disease. Curr Med Chem 2008, 15:1863-1869
3. Zipp F, Aktas O: The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends Neurosci 2006, 29:518-527
4. Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006, 12:1005-1015
5. Miller KR, Streit WJ: The effects of aging, injury and disease on microglial function: a case for cellular senescence. Neuron Glia Biol 2007, 3:245-253
6. Shie FS, Breyer RM, Montine TJ: Microglia lacking E prostanoid receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity. Am J Pathol 2005, 166:1163-1172
7. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, Fitzgerald KA, Latz E, Moore KJ, Golenbock DT: The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol 2008, 9:857-865
8. Hickman SE, Allison EK, El Khoury J: Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosci 2008, 28:8354-8360
9. Liang X, Wang Q, Hand T, Wu L, Breyer RM, Montine TJ, Andreasson K: Deletion of the prostaglandin E2 EP2 receptor reduces oxidative damage and amyloid burden in a model of Alzheimer's disease. J Neurosci 2005, 25:10180-10187
10. Ahmad AS, Yun YT, Ahmad M, Maruyama T, Dore S: Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation. Neurotox Res 2008, 14:343-351
11. Jin J, Shie FS, Liu J, Wang Y, Davis J, Schantz AM, Montine KS, Montine TJ, Zhang J: Prostaglandin E2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J Neuroinflammation 2007, 4:2
12. Manabe Y, Anrather J, Kawano T, Niwa K, Zhou P, Ross ME, Iadecola C: Prostanoids, not reactive oxygen species, mediate COX-2-dependent neurotoxicity. Ann Neurol 2004, 55:668-675
13. Wu L, Wang Q, Liang X, Andreasson K: Divergent effects of prostaglandin receptor signaling on neuronal survival. Neurosci Lett 2007, 421:253-258
14. McGeer PL, McGeer EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging 2007, 28:639-647
15. Group AR, Lyketsos CG, Breitner JC, Green RC, Martin BK, Meinert C, Piantadosi S, Sabbagh M: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808
16. Konstantinopoulos PA, Lehmann DF: The cardiovascular toxicity of selective and nonselective cyclooxygenase inhibitors: comparisons, contrasts, and aspirin confounding. J Clin Pharmacol 2005, 45:742-750
17. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M: Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 2008, 65:896-905
18. Echeverria V, Clerman A, Dore S: Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci 2005, 22:2199-2206
19. Montine TJ, Milatovic D, Gupta RC, Valyi-Nagy T, Morrow JD, Breyer RM: Neuronal oxidative damage from activated innate immunity is EP2 receptor-dependent. J Neurochem 2002, 83:463-470
20. Shie FS, Montine KS, Breyer RM, Montine TJ: Microglial EP2 is critical to neurotoxicity from activated cerebral innate immunity. Glia 2005, 52:70-77
21. Funk CD, FitzGerald GA: COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol 2007, 50:470-479
22. Yu Y, Fan J, Chen XS, Wang D, Klein-Szanto AJ, Campbell RL, FitzGerald GA, Funk CD: Genetic model of selective COX2 inhibition reveals novel heterodimer signaling. Nat Med 2006, 12:699-704
23. Yu Y, Fan J, Hui Y, Rouzer CA, Marnett LJ, Klein-Szanto AJ, FitzGerald GA, Funk CD: Targeted cyclooxygenase gene (ptgs) exchange reveals discriminant isoform functionality. J Biol Chem 2007, 282:1498-1506
24. Nishihara H, Kobayashi S, Hashimoto Y, Ohba F, Mochizuki N, Kurata T, Nagashima K, Matsuda M: Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins. Biochim Biophys Acta 1999, 1452:179-187
25. Fukui Y, Hashimoto O, Sanui T, Oono T, Koga H, Abe M, Inayoshi A, Noda M, Oike M, Shirai T, Sasazuki T: Haematopoietic cell-specific CDM family protein DOCK2 is essential for lymphocyte migration. Nature 2001, 412:826-831
26. Janardhan A, Swigut T, Hill B, Myers MP, Skowronski J: HIV-1 Nef binds the DOCK2-ELMO1 complex to activate rac and inhibit lymphocyte chemotaxis. PLoS Biol 2004, 2:E6
27. Nishihara H, Maeda M, Oda A, Tsuda M, Sawa H, Nagashima K, Tanaka S: DOCK2 associates with CrkL and regulates Rac1 in human leukemia cell lines. Blood 2002, 100:3968-3974
28. Nishihara H, Maeda M, Tsuda M, Makino Y, Sawa H, Nagashima K, Tanaka S: DOCK2 mediates T cell receptor-induced activation of Rac2 and IL-2 transcription. Biochem Biophys Res Commun 2002, 296:716-720
29. Sanui T, Inayoshi A, Noda M, Iwata E, Oike M, Sasazuki T, Fukui Y: DOCK2 is essential for antigen-induced translocation of TCR and lipid rafts, but not PKC-theta and LFA-1, in T cells. Immunity 2003, 19:119-129
30. Sanui T, Inayoshi A, Noda M, Iwata E, Stein JV, Sasazuki T, Fukui Y: DOCK2 regulates Rac activation and cytoskeletal reorganization through interaction with ELMO1. Blood 2003, 102:2948-2950
31. Shulman Z, Pasvolsky R, Woolf E, Grabovsky V, Feigelson SW, Erez N, Fukui Y, Alon R: DOCK2 regulates chemokine-triggered lateral lymphocyte motility but not transendothelial migration. Blood 2006, 108:2150-2158
32. Kitamura Y, Shibagaki K, Takata K, Tsuchiya D, Taniguchi T, Gebicke-Haerter PJ, Miki H, Takenawa T, Shimohama S: Involvement of Wiskott-Aldrich syndrome protein family verprolin-homologous protein (WAVE) and Rac1 in the phagocytosis of amyloid-beta(1-42) in rat microglia. J Pharmacol Sci 2003, 92:115-123
33. Ohsawa K, Imai Y, Kanazawa H, Sasaki Y, Kohsaka S: Involvement of Iba1 in membrane ruffling and phagocytosis of macrophages/microglia. J Cell Sci 2000, 113 (Pt 17):3073-3084
34. Kunisaki Y, Nishikimi A, Tanaka Y, Takii R, Noda M, Inayoshi A, Watanabe K, Sanematsu F, Sasazuki T, Sasaki T, Fukui Y: DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis. J Cell Biol 2006, 174:647-652
35. Kunisaki Y, Tanaka Y, Sanui T, Inayoshi A, Noda M, Nakayama T, Harada M, Taniguchi M, Sasazuki T, Fukui Y: DOCK2 is required in T cell precursors for development of Valpha14 NK T cells. J Immunol 2006, 176:4640-4645
36. Mildner A, Schmidt H, Nitsche M, Merkler D, Hanisch UK, Mack M, Heikenwalder M, Bruck W, Priller J, Prinz M: Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci 2007, 10:1544-1553
37. Mir M, Tolosa L, Asensio VJ, Llado J, Olmos G: Complementary roles of tumor necrosis factor alpha and interferon gamma in inducible microglial nitric oxide generation. J Neuroimmunol 2008, 204: 101-109
38. Sawada M, Kondo N, Suzumura A, Marunouchi T: Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 1989, 491:394-397
39. Sheehan JJ, Zhou C, Gravanis I, Rogove AD, Wu YP, Bogenhagen DF, Tsirka SE: Proteolytic activation of monocyte chemoattractant protein-1 by plasmin underlies excitotoxic neurodegeneration in mice. J Neurosci 2007, 27:1738-1745
40. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP: Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTPinduced neurotoxicity: role of TNF-alpha. FASEB J 2006, 20:670-682
41. Thompson WL, Karpus WJ, Van Eldik LJ: MCP-1-deficient mice show reduced neuroinflammatory responses and increased peripheral inflammatory responses to peripheral endotoxin insult. J Neuroinflammation 2008, 5:35
42. Yamamoto M, Kiyota T, Walsh SM, Liu J, Kipnis J, Ikezu T: Cytokine-mediated inhibition of fibrillar amyloid-beta peptide degradation by human mononuclear phagocytes. J Immunol 2008, 181:3877-3886
43. Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S: Expression of CCR2 in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci 2007, 27:12396-12406
44. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C: Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006, 12:225-229
45. Klegeris A, McGeer PL: Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity. Neurobiol Aging 2002, 23:787-794
46. Levi G, Minghetti L, Aloisi F: Regulation of prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions. Biochimie 1998, 80:899-904
47. Andjelkovic AV, Nikolic B, Pachter JS, Zecevic N: Macrophages/microglial cells in human central nervous system during development: an immunohistochemical study. Brain Res 1998, 814:13-25
48. Mannoji H, Yeger H, Becker LE: A specific histochemical marker (lectin Ricinus communis agglutinin-1) for normal human microglia, and application to routine histopathology. Acta Neuropathol 1986, 71:341-343
49. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB: In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-467
50. Mackenzie IR, Hao C, Munoz DG: Role of microglia in senile plaque formation. Neurobiol Aging 1995, 16:797-804
51. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC: Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 2003, 24:321-331
52. Xiang Z, Haroutunian V, Ho L, Purohit D, Pasinetti GM: Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia. Dis Markers 2006, 22:95-102
53. El Khoury J, Luster AD: Mechanisms of microglia accumulation in Alzheimer's disease: therapeutic implications. Trends Pharmacol Sci 2008, 29:626-632
54. Gotoh K, Tanaka Y, Nishikimi A, Inayoshi A, Enjoji M, Takayanagi R, Sasazuki T, Fukui Y: Differential requirement for DOCK2 in migration of plasmacytoid dendritic cells versus myeloid dendritic cells. Blood 2008, 111:2973-2976
55. Nishikimi A, Fukuhara H, Su W, Hongu T, Takasuga S, Mihara H, Cao Q, Sanematsu F, Kanai M, Hasegawa H, Tanaka Y, Shibasaki M, Kanaho Y, Sasaki T, Frohman MA, Fukui Y: Sequential Regulation of DOCK2 Dynamics by Two Phospholipids during Neutrophil Chemotaxis. Science 2009, 324:384-387
56. Roepstorff K, Rasmussen I, Sawada M, Cudre-Maroux C, Salmon P, Bokoch G, van Deurs B, Vilhardt F: Stimulus-dependent regulation of the phagocyte NADPH oxidase by a VAV1. Rac1, and PAK1 signaling axis. J Biol Chem 2008, 283:7983-7993
57. Shah VB, Ozment-Skelton TR, Williams DL, Keshvara L: Vav1 and PI3K are required for phagocytosis of beta-glucan and subsequent superoxide generation by microglia. Mol Immunol 2009, 46: 1845-1853
58. Vilhardt F, Plastre O, Sawada M, Suzuki K, Wiznerowicz M, Kiyokawa E, Trono D, Krause KH: The HIV-1 Nef protein and phagocyte NADPH oxidase activation. J Biol Chem 2002, 277:42136-42143
59. Wilkinson B, Koenigsknecht-Talboo J, Grommes C, Lee CY, Landreth G: Fibrillar beta-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J Biol Chem 2006, 281:20842-20850
60. Choi SH, Lee DY, Kim SU, Jin BK: Thrombin-induced oxidative stress contributes to the death of hippocampal neurons in vivo: role of microglial NADPH oxidase. J Neurosci 2005, 25:4082-4090
61. Kim HS, Ye SK, Cho IH, Jung JE, Kim DH, Choi S, Kim YS, Park CG, Kim TY, Lee JW, Chung MH: 8-hydroxydeoxyguanosine suppresses NO production and COX-2 activity via Rac1/STATs signaling in LPS-induced brain microglia. Free Radic Biol Med 2006, 41:1392-1403
62. Wilkinson BL, Landreth GE: The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J Neuroinflammation 2006, 3:30
63. Persaud-Sawin DA, Banach L, Harry GJ: Raft aggregation with specific receptor recruitment is required for microglial phagocytosis of Abeta42. Glia 2009, 57:320-335